TCRX Q2 2021 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$65M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M

Gross Profit

-$8M-279.2% margin

Operating Income

-$11M-375.0% margin

Net Income

-$11M-374.8% margin

EPS (Diluted)

$-0.45

QoQ Revenue Growth

+40.5%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$15M

Stock-Based Comp.

$503,000

Balance Sheet

Total Assets

$130M

Total Liabilities

$31M

Stockholders' Equity

$99M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$0	—
Gross Profit	-$8M	-$5M	-76.7%
Operating Income	-$11M	-$6M	-90.2%
Net Income	-$11M	-$6M	-90.2%